Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Itamar Raz

Showing results (211-220 of 254) with videos related to

Pageof 26
Sort By:
Circulation|February 22, 2019
Comparison of the Effects of Glucagon-Like Peptide Receptor Agonists and Sodium-Glucose Cotransporter 2 Inhibitors for Prevention of Major Adverse Cardiovascular and Renal Outcomes in Type 2 Diabetes MellitusThomas A Zelniker, Stephen D Wiviott, Itamar Raz, et al.
Lancet (London, England)|November 15, 2018
SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trialsThomas A Zelniker, Stephen D Wiviott, Itamar Raz, et al.
Diabetes Care|January 11, 2022
Association of Baseline HbA1c With Cardiovascular and Renal Outcomes: Analyses From DECLARE-TIMI 58Avivit Cahn, Stephen D Wiviott, Ofri Mosenzon, et al.
Diabetes Care|March 3, 2021
Cardiovascular, Renal, and Metabolic Outcomes of Dapagliflozin Versus Placebo in a Primary Cardiovascular Prevention Cohort: Analyses From DECLARE-TIMI 58Avivit Cahn, Itamar Raz, Lawrence A Leiter, et al.
The Journal of Clinical Endocrinology and Metabolism|January 15, 2021
Stuttering and Incident Type 2 Diabetes: A Population-Based Study of 2.2 Million AdolescentsAvishai M Tsur, Shir Hershkovich, Inbar Zucker, et al.
Annals of Internal Medicine|April 2, 2003
Cardiovascular outcomes in the Irbesartan Diabetic Nephropathy Trial of patients with type 2 diabetes and overt nephropathyTomas Berl, Lawrence G Hunsicker, Julia B Lewis, et al.
Diabetes, Obesity & Metabolism|January 12, 2018
DECLARE-TIMI 58: Participants' baseline characteristicsItamar Raz, Ofri Mosenzon, Marc P Bonaca, et al.
Diabetes Care|November 18, 2022
Efficacy and Safety of Dapagliflozin by Baseline Insulin Regimen and Dose: Post Hoc Analyses From DECLARE-TIMI 58Rena Pollack, Itamar Raz, Stephen D Wiviott, et al.
Circulation|September 3, 2019
Heart Failure Risk Stratification and Efficacy of Sodium-Glucose Cotransporter-2 Inhibitors in Patients With Type 2 Diabetes MellitusDavid D Berg, Stephen D Wiviott, Benjamin M Scirica, et al.
Journal of the American Society of Nephrology : JASN|June 3, 2005
Impact of achieved blood pressure on cardiovascular outcomes in the Irbesartan Diabetic Nephropathy TrialTomas Berl, Lawrence G Hunsicker, Julia B Lewis, et al.
Pageof 26

Showing results (211-220 of 254) with videos related to

Sort By:
Pageof 26
Circulation|February 22, 2019
Comparison of the Effects of Glucagon-Like Peptide Receptor Agonists and Sodium-Glucose Cotransporter 2 Inhibitors for Prevention of Major Adverse Cardiovascular and Renal Outcomes in Type 2 Diabetes MellitusThomas A Zelniker, Stephen D Wiviott, Itamar Raz, et al.
Lancet (London, England)|November 15, 2018
SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trialsThomas A Zelniker, Stephen D Wiviott, Itamar Raz, et al.
Diabetes Care|January 11, 2022
Association of Baseline HbA1c With Cardiovascular and Renal Outcomes: Analyses From DECLARE-TIMI 58Avivit Cahn, Stephen D Wiviott, Ofri Mosenzon, et al.
Diabetes Care|March 3, 2021
Cardiovascular, Renal, and Metabolic Outcomes of Dapagliflozin Versus Placebo in a Primary Cardiovascular Prevention Cohort: Analyses From DECLARE-TIMI 58Avivit Cahn, Itamar Raz, Lawrence A Leiter, et al.
The Journal of Clinical Endocrinology and Metabolism|January 15, 2021
Stuttering and Incident Type 2 Diabetes: A Population-Based Study of 2.2 Million AdolescentsAvishai M Tsur, Shir Hershkovich, Inbar Zucker, et al.
Annals of Internal Medicine|April 2, 2003
Cardiovascular outcomes in the Irbesartan Diabetic Nephropathy Trial of patients with type 2 diabetes and overt nephropathyTomas Berl, Lawrence G Hunsicker, Julia B Lewis, et al.
Diabetes, Obesity & Metabolism|January 12, 2018
DECLARE-TIMI 58: Participants' baseline characteristicsItamar Raz, Ofri Mosenzon, Marc P Bonaca, et al.
Diabetes Care|November 18, 2022
Efficacy and Safety of Dapagliflozin by Baseline Insulin Regimen and Dose: Post Hoc Analyses From DECLARE-TIMI 58Rena Pollack, Itamar Raz, Stephen D Wiviott, et al.
Circulation|September 3, 2019
Heart Failure Risk Stratification and Efficacy of Sodium-Glucose Cotransporter-2 Inhibitors in Patients With Type 2 Diabetes MellitusDavid D Berg, Stephen D Wiviott, Benjamin M Scirica, et al.
Journal of the American Society of Nephrology : JASN|June 3, 2005
Impact of achieved blood pressure on cardiovascular outcomes in the Irbesartan Diabetic Nephropathy TrialTomas Berl, Lawrence G Hunsicker, Julia B Lewis, et al.
Pageof 26